Folate-appended cyclodextrin carrier targets ovarian cancer cells expressing the proton-coupled folate transporter.

ABSTRACT: Folate receptor alpha (FRα) is overexpressed in >80% of epithelial ovarian cancer (EOC). Accordingly, folate is attracting attention as a targeting ligand for EOC. For EOC patients, paclitaxel (PTX) is generally used as a first-line chemotherapeutic agent in combination with platinum-based drugs. Cyclodextrin (CyD) is a potential new formulation vehicle for PTX that could replace Cremophor-EL, a traditional formulation vehicle that causes significant side effects, including neutropenia. Several years ago, folate-appended β-CyD (Fol-c1 -β-CyD) was developed as an FRα-targeting drug carrier, but its efficacy as a treatment for EOC remains to be determined. In this study, we assessed the antitumor activity of PTX in Fol-c1 -β-CyD (PTX/Fol-c1 -β-CyD) in EOC-derived cell lines. We found that PT

SUBMITTER: Saito S 

PROVIDER: S-EPMC7226238 | biostudies-literature | 2020 May

REPOSITORIES: biostudies-literature